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ABSTRACT
Background and aims Wastewater-based epidemiology is an additional indicator of drug use that is gaining reliability to
complement the current established panel of indicators. The aims of this study were to: (i) assess spatial and temporal
trends of population-normalized mass loads of benzoylecgonine, amphetamine, methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA) in rawwastewater over 7 years (2011–17); (ii) address overall drug use by es-
timating the average number of combined doses consumed per day in each city; and (iii) compare these with existing preva-
lence and seizure data. Design Analysis of daily raw wastewater composite samples collected over 1 week per year from
2011 to 2017. Setting and Participants Catchment areas of 143 wastewater treatment plants in 120 cities in 37 coun-
tries.Measurements Parent substances (amphetamine, methamphetamine and MDMA) and the metabolites of cocaine
(benzoylecgonine) and ofΔ9-tetrahydrocannabinol (11-nor-9-carboxy-Δ9-tetrahydrocannabinol) weremeasured inwaste-
water using liquid chromatography–tandemmass spectrometry. Daily mass loads (mg/day) were normalized to catchment
population (mg/1000 people/day) and converted to the number of combined doses consumed per day. Spatial differences
were assessedworld-wide, and temporal trends were discerned at European level by comparing 2011–13 drug loads versus
2014–17 loads. Findings Benzoylecgonine was the stimulant metabolite detected at higher loads in southern and west-
ern Europe, and amphetamine, MDMA and methamphetamine in East and North–Central Europe. In other
continents, methamphetamine showed the highest levels in the United States and Australia and benzoylecgonine in South
America. During the reporting period, benzoylecgonine loads increased in general across Europe, amphetamine andmeth-
amphetamine levels fluctuated andMDMAunderwent an intermittent upsurge. Conclusions The analysis of wastewater
to quantify drug loads provides near real-time drug use estimates that globally correspond to prevalence and seizure data.
Keywords Amphetamine, cocaine, ecstasy/MDMA, illicit drugs, methamphetamine, wastewater-based epidemiology.
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INTRODUCTION
The global illicit drug market is estimated to be a hundred-
billion activity that facilitates corruption, affects the eco-
nomic development of certain regions in the world [1,2],
and contributes to the global burden of disease [3]. In eco-
nomically developed regions, the disease burden from illicit
psychoactive substance use is higher than in less developed
regions and, compared to legal substances such as alcohol
and tobacco, inflicts mortality earlier in life [4].
Determining the scale of the illicit drug market and its
temporal dynamics is an important but challenging task
for law and drug enforcement agencies to assess the effi-
cacy of drug-related policy and control/prevention mea-
sures. Historically, this has been established through a
combination of seizures, surveys, drug treatment demands,
drug-related hospital admissions and arrest data.
Wastewater-based epidemiology (WBE) uses the analysis
of illicit drug residues in wastewater to provide a quantita-
tive measure of the mass loads of a drug released in a spe-
cific sewer catchment. Mass loads are normalized by the
population size to provide the daily load released per
1000 people. Uncertainties associated with WBE measure-
ments of drug loads, derived from in-sewer phenomena,
sewage sampling and analysis and population size estima-
tions, are typically < 20% when studies are performed fol-
lowing the best practice protocol [5,6] developed by the
Sewage Analysis CORe Group Europe [7]. Estimates of drug
consumption are affected by additional sources of uncer-
tainty, i.e. excretion factors, mass doses and drug purity
(Supporting information, Appendix S1).
In 2011, WBE was applied in the first international as-
sessment of illicit drug use scenario in 19 European cities
through the analysis of residues of five selected illicit drugs
[cocaine, cannabis, amphetamine, methamphetamine and
methylenedioxymethamphetamine (MDMA)] in raw
wastewater [8]. The monitoring was repeated every year
to expand the spatial coverage and obtain consistent
long-term data [9]. The number of cities increased from
19 (covering 14.1 million people) in 2011 to 73 (covering
37.9 million people) in 2017 (Fig. 1), and the monitoring
was extended to Australia (AU), New Zealand (NZ),
Colombia (CO), Martinique (MQ), Canada (CA), the
United States (US), South Korea (KR) and Israel (IL). Thus,
the aims of this study were to: (i) assess spatial and tempo-
ral trends in drug use by measuring benzoylecgonine, am-
phetamine, methamphetamine and MDMA mass loads in
raw wastewater throughout 7 years; and (ii) address over-
all drug use by estimating the average number of combined
doses consumed per day in each city. Results of 11-nor-9-
carboxy-Δ9-tetrahydrocannabinol (THC-COOH, metabolite
of Δ9-tetrahydrocannabinol) are provided in Supporting in-
formation, Appendix S1 due to the challenges of its quanti-
fication in wastewater, which were assessed during the
7 years of study and, therefore, do not lead to readily com-
parable drug use figures [10].
METHODS
Sampling
Every wastewater treatment plant (WWTP) provided al-
iquots of composite samples from the influent,
representing raw wastewater over a 24-hour period.
Typically, samples were obtained for 7 consecutive days
in March or April every year. A ‘normal’ week was
targeted, avoiding special events such as public holidays
or festivals. Population size, percentage of city population
covered by each WWTP, sampling mode and dates are
provided in Tables S1 and S2 of Supporting information,
Appendix S1. The ISO 3166-1 alpha-2 code is used
there and throughout the text to abbreviate country
names. Figure 1 shows the level of participation per
year. During the first 3 years (2011–13 [8,9]) only
European cities were monitored while, from 2014 on-
wards, cities in AU, NZ, CO, MQ, CA, US, KR and IL also
participated in the sampling campaign (Fig. 1). During
the reporting period, wastewater from more than 60
million people, connected to 143 individual WWTPs in
120 cities in 37 countries, was analysed at least once
over 1 week. Twenty-six cities from 14 European coun-
tries (29 WWTPs with approximately 19.3 million peo-
ple connected) provided data for 5 or more years,
building a core data set essential to assess temporal
changes. A questionnaire was sent to WWTP managers
each year before the start of the sampling campaign to
gather information on WWTP catchment areas, appro-
priateness of sampling and details of the monitoring
period [6].
Analytical methodology
The analytical procedures applied for the determination of
illicit drugs and their metabolites in wastewater have
changed little since the first study in 2011 [8], except for
certain modifications and improvements derived from a
better understanding of the fate of biomarkers in sewers
[11], particularly in the case of THC-COOH [10]. Partici-
pants employed validated analytical methodologies, which
generally consisted of: (i) spiking samples with stable
isotope-labelled internal standards (SILIS) for each analyte,
in order to correct for matrix interferences and/or losses
during sample treatment; (ii) filtration or centrifugation of
samples to remove solid particles; (iii) off-line solid-phase
extraction (SPE) for pre-concentration and clean-up; and
(iv) analysis by liquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS). More details on analytical
methodologies are available in Hernández et al. [12].
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Load, dose calculations and comparison with established
drug use indicators
Parent substances (amphetamine, methamphetamine and
MDMA) and two urinary metabolites (benzoylecgonine
for cocaine and THC-COOH for cannabis) were measured
in influent wastewater. Concentrations (ng/l) were multi-
plied by wastewater daily flow rates (l/day) and divided by
the population served by each WWTP to gain population-
normalized loads (mg/1000 people/day). Means, standard
deviations, maximum and minimum values for every sub-
stance, city and year are available through an open on-line
repository [13]. These figures are not provided for regions
(i.e. North or South Europe) due to the coexistence of cities
with very low and very high population-normalized loads
in the same region. Alternatively, two types of overall
means were calculated: (i) all cities in a specific year
(dashed lines on the right side of figures in Supporting in-
formation, Appendix S2); and (ii) cities that provided data
for 5 or more years (dotted lines). Locations were excluded
from the overall mean calculation if: (i) all concentrations
within a week were < LOQ (i.e. below the limit of quantifi-
cation of the method); and (ii) an abnormally high or low
value was reported for at least 1 year [e.g. Eindhoven
(NL) for amphetamine and MDMA; see sections on
‘Amphetamine’ and ‘MDMA’]). Cities reporting at least
one concentration > LOQ within 1 week were considered
by replacing values< LOQ by 0.5 × LOQ. Maps and graphs
summarizing all results were created using R [14].
Figures 2–5 allow: (i) gaining a quick spatial overview, (ii)
comparing new (2014–17) and previously published data
(2011–13 [8,9]) by the size of the semicircles; and (iii)
assessing temporal trends within each period by the colour
of the semicircles. An increase or decrease was assigned if
the slope from a linear regression was significantly different
from zero (P < 0.2). No trend was assigned if only two ob-
servations were available within a period or if Pwas> 0.2.
Average excretion rate coefficients for each
metabolite/residue [15,16] and average doses of the par-
ent drug (Table S3 of Supporting information, Appendix
S1 [17,18]) were applied to population-normalized mass
loads to gain an estimated number of pure doses con-
sumed per day. Doses of cocaine, amphetamine, metham-
phetamine and MDMA were then summed to acquire the
number of combined doses consumed per day.
Amphetamine use was estimated from the entire loads
of this compound, despite other sources that may contrib-
ute to its presence in wastewater: amphetamine disposal,
licit-prescribed use of amphetamine or methamphetamine
metabolism. Accordingly, methamphetamine consump-
tion was derived from methamphetamine loads solely.
Cannabis (estimated from THC-COOH) was excluded from
combined doses calculations due to the higher uncer-
tainty in its WBE-derived use estimations [10,19]. Results
Figure 1 Participation in terms of (millions of) population covered and number of countries, cities, wastewater treatment plants and laboratories
participating per year. Cities with a red star provided data for at least 5 years during 2011–17.      [Colour figure can be viewed at wileyonlinelibrary.com]
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for THC-COOH are provided in Supporting information,
Appendices S1 and S2.
European WBE results were compared to established
epidemiological indicators of drug use, i.e. seizure
statistics, purity and price data and prevalence estimates
derived from population surveys and indirect statistical
methods [1,2]. As the information provided by these indi-
cators and WBE is not directly comparable, a qualitative
analysis showed the points of agreement/disagreement
and the potential complementarity of both methodologies.
Results from cities outside Europe were excluded from
these analyses due to the limited number of sites and
years monitored, and were insufficient to extrapolate
spatial and temporal trends.
Uncertainties related to WBE
WBE data are subject to different uncertainties (Table S4 of
Supporting information, Appendix S1). While participating
laboratories’ performance of chemical analysis was system-
atically checked through yearly interlaboratory studies
[19,20], not all other aspects could be quantified accu-
rately in such a large-scale study with reasonable efforts.
However, with spatial differences of WBE results spanning
more than two orders of magnitude among locations for
all substances, uncertainties seem to play a subordinate
role.
Random uncertainties mainly affect the assessment of
temporal changes within one location. In view of monitor-
ing 1 week per year only, apparent short-term trends
should be interpreted with caution.
Systematic uncertainties, e.g. inaccurate population
size or neglecting in-sewer transformation, can lead to sys-
tematic under- or overestimation. This affects assessing
spatial differences of drug residues in sewers and calcula-
tion of consumption estimates. In-sewer processes
(exfiltration and transformation) would lead to an underes-
timation of drug loads entering the sewer system. Recent
laborious laboratory and full-scale studies indicate that this
underestimation is smaller than 10% for benzoylecgonine,
methamphetamine and MDMA for typical hydraulic resi-
dence times (< 12 hours) under most conditions [15,21].
Only amphetamine is susceptible to higher transforma-
tions, which may lead to a site-specific underestimation
of consumption, as a global correction factor cannot be
applied. Unconsumed cocaine dumped into sewers would
lead to elevated benzoylecgonine loads. This can be
discovered with abnormally high cocaine to
benzoylecgonine ratios, as not all cocaine will transform
to benzoylecgonine.
Figure 2 Mean population-normalized benzoylecgonine loads (mg/1000 people/day) 2011–13 versus 2014–17. [Colour figure can be viewed at
wileyonlinelibrary.com]
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RESULTS
Cocaine
Benzoylecgonine, a biomarker of cocaine consumption,
was one of the substances measured at highest levels in Eu-
ropean wastewaters during the 7 years. Wide spatial differ-
ences observed during the early monitoring campaigns in
2011–13 [8,9] were confirmed in 2014–17 (Fig. 2).
Population-normalized loads were generally higher in
southern and western cities compared to eastern and
northern locations. The highest weekly mean values
(600–900 mg benzoylecgonine/1000 people/day) were
found in London (UK), Bristol (UK), Amsterdam (NL),
Zurich (CH), Geneva (CH), St Gallen (CH) and Antwerp
(BE) (Supporting information, Appendix S2). In most of
the countries where several locations were studied (BE,
NL, DE, CH, ES), population-normalized loads were higher
in large cities compared to smaller towns (Supporting infor-
mation, Appendix S2). This pattern had already been re-
ported by Ort et al. [9] and had been observed in national
studies in BE [22], FR [23], IT [24], CH [25] and FI [26].
In terms of temporal trends, population-normalized
mean loads were higher (depicted with a larger semicircle)
in 2014–17 compared to 2011–13 in Barcelona (ES),
Lisbon (PT), Geneva (CH), Zurich (CH), St Gallen (CH),
Zagreb (HR), Bratislava (SK), Brussels (BE), Amsterdam
(NL), London (GB), Copenhagen (DK) and Oslo (NO). In
nine cities (Barcelona, Geneva, Zurich, St Gallen, Bristol,
Milan, Dortmund, Dulmen and Zagreb) a significant in-
creasing trend was also observed during the last 4 years
(green semicircle). When considering only the cities that
provided data for at least 5 years, overall mean
benzoylecgonine loads increased from 281–331 mg/1000
people/day in 2011–13 to 329–373 mg/1000 people/day
in 2014–17 (dotted lines in Supporting information,
Appendix S2).
Population-normalized mass loads of benzoylecgonine
were relatively high in South American locations com-
pared to other regions outside Europe (Fig. 2). MQ is located
close to the cocaine trade routes, whichwas reflected in the
levels of benzoylecgonine measured in wastewater. The
three North American cities showed a higher prevalence
of cocaine use than the Australasian cities. In both regions,
an increasing trend was observed in the participating loca-
tions with long-term data.
Amphetamine
In Europe, the highest population-normalizedmass loads of
amphetamine were found in cities from BE and NL, in some
cases exceeding by far the mean loads found in the rest of
the continent (Fig. 3 and Supporting information,
Figure 3 Mean population-normalized amphetamine loads (mg/1000 people/day) 2011–13 versus 2014–17. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Appendix S2). The frequent high values measured in
Eindhoven were attributed to direct discharges of drug
manufacturing wastes [27,28] and, consequently, ex-
cluded from the calculation of overall means (see section:
‘Load, dose calculations and comparison with established
drug use indicators’). Loads reported in the Swedish
cities and in Reykjavík (IS), despite being monitored for
only 1–3 years, suggest a high use of amphetamine in
northern European countries, matching the trend previ-
ously detected in some Finnish cities and in Oslo (NO)
[29]. DE also exhibited high loads of amphetamine, al-
though with a great variation among cities. Compara-
tively, loads measured in southern European cities were
much lower.
A significant increasing trend was observed within
2014–17 in Barcelona (ES), Geneva (CH), Berne (CH),
Zurich (CH), Dortmund (DE) and Berlin (DE), and no de-
creasing trends were observed. However, overall
population-normalized mean loads from the cities that pro-
vided data for 5 or more years, including all these locations
except Berlin, showed no apparent major change during
2011–17 (ca. 40 mg/1000 people/day, Supporting infor-
mation, Appendix S2).
Outside Europe, amphetamine loads were typically
low, and may be largely attributable to methamphetamine
metabolism [30] and to the use of prescribed am-
phetamine [31].
Methamphetamine
Although the average use of methamphetamine in
Europe is low when compared to other stimulants, some
localized hotspots were identified, mostly in eastern coun-
tries. Bratislava (SK), Piestany (SK), Prague (CZ), Budweis
(CZ), Brno (CZ), Dresden (DE), Chemnitz (DE), Erfurt (DE)
and Oslo (NO) showed the highest population-normalized
loads in wastewater, with weekly mean values exceeding
150 mg/1000 people/day (Supporting information,
Appendix S2). Some cities in FI and CH reported year-
to-year increases in the loads measured over 2014–17,
although this increase was only statistically significant
in Tampere (FI), Zurich (CH) and Geneva (CH). Interest-
ingly, the opposite trend was shown in Oslo (NO), a city
which had previously ranked very high regarding meth-
amphetamine use (Fig. 4). Considering the overall means
from locations providing data for 5 or more years, a de-
crease of more than 50% was observed from 2011
(39 mg/1000 people/day) to 2013 (18 mg/1000
people/day), followed by a steady increase up to
Figure 4 Mean population-normalized methamphetamine loads (mg/1000 people/day) 2011–13 versus 2014–17. [Colour figure can be viewed at
wileyonlinelibrary.com]
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31 mg/1000 people/day in 2017 (Supporting informa-
tion, Appendix S2).
Unlike the European overview, methamphetamine
dominated the drug landscape in the cities monitored in
North America (US and CA) and Australasia (AU, NZ and
KR). Population-normalized mass loads exceeded those in
eastern Europe, where methamphetamine consumption is
considered to be high (Fig. 4). In Busan (KR) metham-
phetamine loads were the highest among the drugs in-
cluded in the study, although they were low compared to
the values reported in North American, Australian and
New Zealand cities. Tel Aviv (IL), Fort de France (MQ)
and Colombian cities showed little evidence of metham-
phetamine consumption.
MDMA
The highest population-normalized mass loads of MDMA
during the 7 years were reported in the Dutch cities of Eind-
hoven, Utrecht and Amsterdam (Fig. 5). Eindhoven and
Utrecht were excluded from overall mean calculations
and trend analyses due to the major impact of direct dis-
posal events, which could originate from discharges under
the pressure of police raids or fly-tipping waste from illicit
drugs synthesis [27]. High loads were also measured in
cities in BE, GB and CH, whereas eastern and southern
European locations showed lower values. As in the case
of cocaine, MDMA population-normalized mass loads were
usually higher in large cities, a trend observed in BE, CH
and DE, but also in historically low-MDMA-usage countries
such as ES, FR and PT (Fig. 5).
In terms of temporal variations, there was a higher
number of cities where MDMA was quantified in 2016
and 2017 compared to earlier years. There was also an
increasing trend in the loads measured, with many of
the cities that were monitored for at least 5 years
reporting an increase from 2011–13 to 2014–17; i.e. Hel-
sinki (FI), Oslo (NO), Amsterdam (NL), Brussels (BE), Dort-
mund (DE), Zagreb (HR), Zurich (CH), Geneva (CH) and
Barcelona (ES) (Fig. 5). However, this upsurge was non-
linear, and there were other large cities where MDMA
loads decreased from 2011–13 to 2014–17, e.g. Milan
(IT). Considering all the cities that provided data for
5 or more years, overall mean loads increased intermit-
tently during 2011–17, reaching a maximum of
33 mg/1000 people/day in 2017 (Supporting informa-
tion, Appendix S2).
Outside Europe, population-normalized mass loads of
MDMA were generally low (Fig. 5). Tel Aviv (IL) was the
only city reporting relatively high MDMA levels compared
to the other drugs. However, even there, MDMA use was
low when compared to European sites.
Figure 5 Mean population-normalized 3,4-methylenedioxymethamphetamine (MDMA) loads (mg/1000 people/day) 2011–13 versus 2014–17.
[Colour figure can be viewed at wileyonlinelibrary.com]
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Consumption estimates: 2011–17 mean of sum of doses
Community drug use was assessed by calculating the
number of combined doses of cocaine, amphetamine,
methamphetamine and MDMA in each city. The highest
numbers were found in Antwerp (BE), Amsterdam (NL),
Zurich (CH), London (GB) and Barcelona (ES), with 43,
33, 28, 28 and 25 combined doses/1000 people/day, re-
spectively (Fig. 6). Conversely, Athens (GR), Almada
(PT), Joensuu (FI), Krakow (PL) and Umeå (SE), with
three, three, two, two and one combined doses/1000
people/day, respectively, were some of the cities with
the lowest rates. The average community drug use for
all the investigated European cities was 13 doses/1000
people/day.
Considering the eight cities with available data dur-
ing the 7 years, a U-shaped curve was observed with
20 and 21 combined doses/1000 people/day in 2011
and 2017, respectively, and a minimum of 15
doses/1000 people/day between 2013 and 2015. Aver-
age combined doses for southwestern European cities
were dominated by cocaine, while methamphetamine
was the predominant drug measured in eastern sites.
The consumption in the Nordic countries and in some
German cities was mainly of amphetamine. Proportions
of MDMA were relatively low for most cities excepting
some locations in NL and FI.
Outside Europe, Medellín (CO), Adelaide (AU) and Seat-
tle (US) had relatively high drug consumption (Fig. 6).
However, Adelaide and Seattle combined doses were
mainly indicative of methamphetamine use [32,33], while
Medellín was due to cocaine consumption, similarly to the
situation in western Europe.
DISCUSSION
Spatial differences
Among the substances investigated, the 2018 European
Drug Report [34] identifies cocaine as the most prevalent
and most frequently seized illicit stimulant in southern
and western Europe. Conversely, amphetamines and
MDMA are reported as themost frequently consumed stim-
ulants in northern and eastern countries, where their sei-
zures are also predominant [34]. These spatial trends
correspond to WBE results (Figs 2–6 and Supporting infor-
mation, Appendix S2): (i) the highest population-
normalized mass loads of benzoylecgonine were measured
in cities in southern and western countries (GB, NL, BE,
CH, ES); (ii) the highest loads of amphetamine were ob-
served in locations from theNordic countries, DE and, espe-
cially, BE and NL; and (iii) the highest levels of MDMAwere
found in BE and NL. The 2016 Drug Markets Report [35]
reports a market expansion of methamphetamine from
Figure 6 2011–17 total average number of doses/1000 people/day.
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[Colour figure can be viewed at wileyonlinelibrary.com]
the East to North and Central Europe, and a similar trend
was observed in this study. The highest methamphetamine
loads were found in eastern locations (CZ, SK and East
German cities such as Chemnitz and Dresden), but high
levels were also reported in Oslo (NO), and some cities in
FI, CH and DE underwent a load increase during 2011–
16. The location of DE in Central Europe confers it a special
character in terms of drug usage, and trends in this country
are better defined by regional geography than by national
boundaries. Amphetamine and cocaine loads dominated
the North and West of the country, in line with
neighbouring cities in BE, NL, DK and SE; metham-
phetamine was found at higher levels in the East, reflecting
a trend with neighbouring cities in CZ.
Amphetamine levels in wastewater need to be
interpreted with caution in regions with high consump-
tion of methamphetamine, such as North America,
Australasia and eastern Europe. Following the administra-
tion of methamphetamine, approximately 4–7% is ex-
creted as amphetamine [36], a percentage that may lead
to non-negligible amounts of this substance in wastewater
[30]. Similarly, if the prescription of amphetamine is high,
levels derived from prescribed use need to be subtracted
from those originated from illicit consumption, a correc-
tion not applied here. For instance, the relatively high
levels of amphetamine found in this study in Seattle are
probably related to its extended use to treat attention
deficit/hyperactivity disorders in the United States [31],
and not to its illicit consumption. Thus, further studies
should separate the different sources contributing to
the presence of a certain drug residue in wastewater.
Amphetamine, methamphetamine and MDMA can also
be directly disposed into sewer systems, and the amount
of drug disposed needs to be differentiated from the
amount excreted (i.e. consumed). This is currently possi-
ble through the application of chiral chromatography
and ‘fingerprint’ analyses. Based on the enantiomerism
and stereoselective metabolism of amphetamine deriva-
tives, these tools have been used to identify dumping phe-
nomena [27,28,37]; characterize methamphetamine
trafficking routes [38]; differentiate between licit and illicit
use of amphetamine [39]; and distinguish amphetamine
residues in wastewater derived from its consumption and
from methamphetamine metabolism [37,40].
Temporal trends
The monitoring of 26 European cities for 5 or more years
allowed discerning temporal trends in drug use. In some
of these cities, population-normalized mass loads of
benzoylecgonine were not only comparatively higher in
2014–17 versus 2011–13, but also increased significantly
within the last period (2014–17). This can indicate either a
higher prevalence of cocaine consumption, a similar
number of users consuming a higher amount of drug or
an increase in the drug purity. Prevalence data suggest
an overall stable use of cocaine throughout Europe and sei-
zures have either remained unchanged or increased
slightly in the last years, but cocaine purity rose on average
~32–54% from 2009 to 2016 [34,41].
For amphetamine and methamphetamine, an individ-
ual comparison of wastewater loads with other drug use in-
dicators is hard to obtain, as both substances are not
distinguished inmany of the established indicator data sets.
This highlights the relevance of WBE, which can comple-
ment classic epidemiological indicators with information
on specific substances to jointly draw a more comprehen-
sive picture of the drug use scenario. Thus, the fluctuations
observed in amphetamine and methamphetamine loads in
northern countries since 2011 [26,29] can reflect a
changing market, with users taking one substance or the
other depending on availability. Users are often unaware
of which of the two drugs they are taking and, while meth-
amphetamine use decreased in Oslo (NO) from 2011 to
2017, the combined use of amphetamine-like stimulants
remained stable.
Both established epidemiological indicators and waste-
water data point to a recent revival of MDMA in Europe
[34]. The number of seizures has increased from approxi-
mately 13000 in 2012 to 24000 in 2016 (85% in-
crease), while prevalence data suggest a stable or
increased use of MDMA in the last years [34,41].
Matching this trend, the overall mean loads for the 26 cit-
ies providing data for 5 or more years increased intermit-
tently since 2011, and the number of cities where
MDMAwas positively quantified in wastewater underwent
an upsurge in 2016–17 compared to previous years. How-
ever, a factor that could contribute to these higher loads is
the known increased content of MDMA in ecstasy tablets
since 2010–11 [42,43].
Combined doses
We acknowledge that back-calculation of doses entails an
additional degree of uncertainty in terms of differing and
variable purity, different administration routes and differ-
ent amounts of drug used over time and among different
locations; however, we calculated the total number of
combined doses because it provides important insights
into the total scale and profile of drug use (Fig. 6). Co-
caine prevalence dominates the southwest of Europe until
the border with BE and CH, where other drug use pat-
terns start to emerge, i.e. amphetamine towards the
North and methamphetamine towards the East and Cen-
tral Europe, the main historical production hotspots. As
previously observed, these results reflect the profiles of
use reported by other epidemiological indicators [34].
Therefore, these complementary data can be used in the
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future to spatially define the impact area of each type of
drug.
CONCLUSIONS
This is the largest WBE study ever performed in terms of
cities (120) and countries (37) involved and of themonitor-
ing duration (2011–17). The extensive data set obtained
for cocaine, amphetamine, methamphetamine and MDMA
showed a comprehensive picture of spatial and temporal
trends of use. Despite the limitation of monitoring few cities
per country and comparing results with national statistics,
the broader WBE picture corresponds to the epidemiologi-
cal indicators considered, e.g. prevalence data and seizures
statistics, demonstrating the capability ofWBE to be used as
an additional and complementary indicator of drug use.
WBE provides updated and objective estimates of drug
use and allows identifying and highlighting new trends
and specific profiles of usemuch earlier than other epidemi-
ological indicators. WBE can serve as an extremely flexible
tool for application at different spatial and temporal scales
and can indicate mitigation measures nearly in real time.
Thus, merging WBE results with information from other
epidemiological indicators can improve our understanding
of the drug use scenario.
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